Gamida Cell (NASDAQ: GMDA) is one of 298 public companies in the "Biotechnology" industry, but how does it contrast to its competitors? We will compare Gamida Cell to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation.
1.7% of Gamida Cell shares are owned by institutional investors. Comparatively, 49.7% of shares of all "Biotechnology" companies are owned by institutional investors. 16.5% of shares of all "Biotechnology" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Gamida Cell and its competitors revenue, earnings per share (EPS) and valuation.
This is a breakdown of recent ratings and price targets for Gamida Cell and its competitors, as reported by MarketBeat.
Gamida Cell presently has a consensus price target of $19.40, indicating a potential upside of 69.43%. As a group, "Biotechnology" companies have a potential upside of 6.52%. Given Gamida Cell's stronger consensus rating and higher possible upside, analysts plainly believe Gamida Cell is more favorable than its competitors.